Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6903)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Mar 27, 2021 (publication date) through Nov 10, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Takahashi K, Kim J, Takahashi A, Hashimoto S, Doi M, Furuya K, Hashimoto R, Owada Y, Ogawa K, Ohara Y, Akashi Y, Hisakura K, Enomoto T, Shimomura O, Noguchi M, Oda T. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report. World J Hepatol 2021; 13(3): 384-392 [PMID: 33815680 DOI: 10.4254/wjh.v13.i3.384] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v13/i3/384.htm |
| Number | Citing Articles |
| 1 |
Yuta Jin, Ryo Nishiyama, Yuta Koganei, Daiki Kimura, Junya Aoyama, Yutaka Nakano, Shunichi Imai, Tatsuya Shimogawara, Toru Yamada, Tomohisa Egawa. Early recurrent hepatocellular carcinoma with portal vein tumor thrombosis successfully treated with rehepatectomy after multimodality treatment with lenvatinib and radiotherapy: A case report. Kanzo 2023; 64(12): 641 doi: 10.2957/kanzo.64.641
|
| 2 |
Junichi Arita, Akihiko Ichida, Rihito Nagata, Yuichiro Mihara, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. Journal of Hepato-Biliary-Pancreatic Sciences 2022; 29(7): 732 doi: 10.1002/jhbp.1135
|
| 3 |
Yutaka Endo, Motohide Shimazu, Tadayuki Sakuragawa, Yusuke Uchi, Motonori Edanami, Ken Sunamura, Soji Ozawa, Naokazu Chiba, Shigeyuki Kawachi. Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report. World Journal of Gastrointestinal Surgery 2022; 14(3): 260-267 doi: 10.4240/wjgs.v14.i3.260
Abstract(504) |
Core Tip(438) |
Full Article(HTML)(2046)
|
Full Article (PDF)-5489K(261)
|
Full Article (Word)-2259K(85)
|
Audio-1916K(1)
|
Peer-Review Report-258K(76)
|
Answering Reviewers-52K(75)
|
Times Cited (0)
|
Total Visits (6657)
|
Open
|
| 4 |
Kaiwu Xu, Cailing Xiang, Zhige Yu, Jia Li, Changjun Liu. Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis. ImmunoTargets and Therapy 2024; : 305 doi: 10.2147/ITT.S458700
|
| 5 |
Hiroyuki Kato, Yukio Asano, Masahiro Ito, Satoshi Arakawa, Masahiro Shimura, Daisuke Koike, Takayuki Ochi, Hironobu Yasuoka, Toki Kawai, Takahiko Higashiguchi, Hiroki Tani, Yoshiki Kunimura, Yuka Kondo, Hidetoshi Nagata, Harunobu Sato, Akihiko Horiguchi. A case of Vp4 hepatocellular carcinoma with tumor thrombosis extending into the confluence of the splenic/portal vein achieved a good prognosis with emergent hepatectomy and postoperative adjuvant therapy with lenvatinib. World Journal of Surgical Oncology 2022; 20(1) doi: 10.1186/s12957-022-02740-w
|
| 6 |
Parissa Tabrizian, Rebecca Marino, Pierce K.H. Chow. Liver resection and transplantation in the era of checkpoint inhibitors. JHEP Reports 2024; 6(11): 101181 doi: 10.1016/j.jhepr.2024.101181
|
| 7 |
Norifumi Iseda, Shinji Itoh, Takeo Toshima, Shohei Yoshiya, Yuki Bekki, Yuriko Tsutsui, Katsuya Toshida, Shoichi Inokuchi, Toru Utsunomiya, Takahiro Tomino, Keishi Sugimachi, Kazutoyo Morita, Mizuki Ninomiya, Noboru Harada, Ryosuke Minagawa, Tomoharu Yoshizumi. Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study. Surgery Today 2024; doi: 10.1007/s00595-024-02930-x
|
| 8 |
Yu Gyoda, Hirofumi Ichida, Fumihiro Kawano, Yoshinori Takeda, Ryuji Yoshioka, Hiroshi Imamura, Yoshihiro Mise, Yuki Fukumura, Akio Saiura. A patient alive without disease 32 months after conversion surgery following lenvatinib treatment for hepatocellular carcinoma with a tumor thrombus originating in the middle hepatic vein and reaching the right atrium via the suprahepatic vena cava: a case report. Clinical Journal of Gastroenterology 2024; 17(2): 311 doi: 10.1007/s12328-023-01909-4
|
| 9 |
Yuta Tai, Yoshifumi Morita, Mitsumasa Makino, Shinya Ida, Ryuta Muraki, Ryo Kitajima, Makoto Takeda, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Hiroya Takeuchi. A Case of Giant Hepatocellular Carcinoma Successfully Treated with Lenvatinib Followed by Parenchymal-Sparing Hepatectomy. The Japanese Journal of Gastroenterological Surgery 2023; 56(10): 547 doi: 10.5833/jjgs.2022.0104
|
| 10 |
Haohao Lu, Chuansheng Zheng, Bin Liang, Xiangwen Xia, Hongjie Fan. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1280837
|
| 11 |
Atsushi Naganuma, Yuhei Suzuki, Takashi Hoshino, Hidetoshi Yasuoka, Yuki Tamura, Hiroaki Naruse, Hiroshi Tanaka, Keitaro Hirai, Ichiro Sakamoto, Tetsushi Ogawa, Takeshi Hatanaka, Satoru Kakizaki. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy. Clinical Journal of Gastroenterology 2022; 15(1): 177 doi: 10.1007/s12328-021-01558-5
|
| 12 |
Ko Oshita, Tsuyoshi Kobayashi, Yosuke Namba, Sotaro Fukuhara, Keiso Matsubara, Daisuke Takei, Ryosuke Nakano, Wataru Okamoto, Hiroshi Sakai, Naoki Tanimine, Takashi Nakahara, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Tomokazu Kawaoka, Kentaro Ide, Michio Imamura, Hiroshi Aikata, Hideki Ohdan. Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study. BMJ Open 2023; 13(10): e073797 doi: 10.1136/bmjopen-2023-073797
|
| 13 |
Junichi Shindoh, Yusuke Kawamura, Masahiro Kobayashi, Norio Akuta, Satoshi Okubo, Masaru Matsumura, Yoshiyuki Suzuki, Masaji Hashimoto. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2022; 26(8): 1637 doi: 10.1007/s11605-022-05388-9
|
| 14 |
Shunji Sano, Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Takeshi Aiyama, Keizo Kazui, Hiroki Shomura, Shinya Ueki, Yuzuru Sakamoto, Chisato Shirakawa, Hirofumi Kamachi, Hirokazu Sugino, Tomoko Mitsuhashi, Akinobu Taketomi. Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma. International Cancer Conference Journal 2022; 12(1): 7 doi: 10.1007/s13691-022-00567-6
|
| 15 |
Yoshifumi Hidaka, Miyo Tomita, Ryosuke Desaki, Masahiro Hamanoue, Sonshin Takao, Mari Kirishima, Takao Ohtsuka. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World Journal of Surgical Oncology 2022; 20(1) doi: 10.1186/s12957-022-02691-2
|
| 16 |
Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama. Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open 2022; 6(6): 427 doi: 10.1002/jgh3.12772
|